SAFETY OF COMBINED PIRFENIDONE AND NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

被引：0

作者：

Flaherty, K. R. ^{[1
]}

Fell, C. D. ^{[2
]}

Huggins, J. T. ^{[3
]}

Nunes, H. ^{[4
]}

Sussman, R. ^{[5
]}

Valenzuela, C. ^{[6
]}

Petzinger, U. ^{[7
]}

Stauffer, J. L. ^{[8
]}

Gilberg, F. ^{[9
]}

Bengus, M. ^{[9
]}

Wijsenbeek, M. ^{[10
]}

机构：

[1] Univ Michigan, Ann Arbor, MI USA

[2] Univ Calgary, Calgary, AB, Canada

[3] Med Univ South Carolina, Charleston, SC USA

[4] Hop Avicenne, Paris, France

[5] Atlantic Hlth Syst, Overlook Med Ctr, Summit, NJ USA

[6] Hosp Univ La Princesa, Inst Invest Princesa, Madrid, Spain

[7] Clinipace Accovion GmbH, Eschborn, Germany

[8] Genentech Inc, San Francisco, CA 94080 USA

[9] F Hoffman La Roche Ltd, Basel, Switzerland

[10] Erasmus Univ, Med Ctr, Rotterdam, Netherlands

来源：

THORAX | 2017年 / 72卷

关键词：

D O I：

10.1136/thoraxjnl-2017-210983.453

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

M31

引用

下载

页码：A253 / A254

页数：2

共 50 条

[41] Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia
Cox, Ingrid A.
de Graaff, Barbara
Corte, Tamera J.
Glaspole, Ian
Chambers, Daniel C.
Moodley, Yuben
Teoh, Alan
Walters, E. Haydn
Palmer, Andrew J.
AUSTRALIAN HEALTH REVIEW, 2021, 45 (06) : 718 - 727
[42] Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, Luca
du Bois, Roland M.
Raghu, Ganesh
Azuma, Arata
Brown, Kevin K.
Costabel, Ulrich
Cottin, Vincent
Flaherty, Kevin R.
Hansell, David M.
Inoue, Yoshikazu
Kim, Dong Soon
Kolb, Martin
Nicholson, Andrew G.
Noble, Paul W.
Selman, Moises
Taniguchi, Hiroyuki
Brun, Michele
Le Maulf, Florence
Girard, Mannaig
Stowasser, Susanne
Schlenker-Herceg, Rozsa
Disse, Bernd
Collard, Harold R.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22): : 2071 - 2082
[43] Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
Kaushal, Mohit
Talwar, Dhruv
Prajapat, Deepak
Kumar, Sunil
Acharya, Sourya
Talwar, Deepak
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (02)
[44] Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
Siri T. Lehtonen
Anniina Veijola
Henna Karvonen
Elisa Lappi-Blanco
Raija Sormunen
Saara Korpela
Ulrika Zagai
Magnus C. Sköld
Riitta Kaarteenaho
Respiratory Research, 17
[45] Pirfenidone and Nintedanib Therapy for Idiopathic Pulmonary Fibrosis: A Tertiary Centre Experience
Diab, N.
Mao, T.
Danoff, S. K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[46] Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
Takeda, Yoshito
Tsujino, Kazuyuki
Kijima, Takashi
Kumanogoh, Atsushi
PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 361 - 370
[47] Indication for and Impact of Switching from Pirfenidone to Nintedanib in Idiopathic Pulmonary Fibrosis
Hogben, C.
Kouranos, V.
Kokosi, M.
Renzoni, E. A.
Chua, F.
Wells, A. U.
Maher, T. M.
Molyneaux, P. L.
George, P. M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[48] Safety and tolerability of combination treatment with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a systemic review and meta-analysis
Lee, Jonghoo
Song, Jae-Uk
JOURNAL OF THORACIC DISEASE, 2023, 15 (11) : 5913 - +
[49] Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis
Roach, Katy
Castells, E.
Tongue, P.
Elliott, G.
Marshall, H.
Richardson, M.
Chachi, L.
Mason, S.
Sutcliffe, A.
Bradding, P.
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[50] Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis
Bonniaud, Philippe
Cottin, Vincent
Spagnolo, Paolo
Nolin, Maeva
Dalon, Faustine
Kirchgassler, Klaus-Uwe
Chia, Jenny
Kamath, Tripthi
Van Ganse, Eric
Belhassen, Manon
EUROPEAN RESPIRATORY JOURNAL, 2020, 56

← 1 2 3 4 5 →